Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Setiptiline is a tetracyclic antidepressant (TeCA) primarily used for the treatment of depression, especially in Japan. It acts as a noradrenergic and specific serotonergic antidepressant. Setiptiline’s mechanism of action includes antagonism at α2-adrenergic receptor, serotonin receptor (notably 5-HT2 subtypes), and histamine H1 receptor. This results in increased noradrenaline release due to presynaptic α2 blockade, modulation of serotonergic signaling via serotonin receptor antagonism or agonism (including potent full agonist activity at 5-HT1E and 5-HT1F receptors), norepinephrine reuptake inhibition, and antihistaminic effects. Its structure is closely related to mianserin and mirtazapine[1][2][3][4][6][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on setiptiline.